Singapore startup Breathonix develops 60-second COVID-19 breathalyzer test

Breathonix develops non-invasive breath tests for disease detection

Breathonix develops non-invasive breath tests for disease detection.

Singapore’s Breathonix has said a clinical trial of its COVID-19 breathalyzer test was able to achieve at least 90% accuracy after screening participants on-site for 60 seconds.

The company’s test uses mass spectrometry to analyze the thousands of volatile organic compounds that people exhale with every breath, to establish a specific signal among those with an active coronavirus infection.

Using a machine learning algorithm, this generates a “bio-fingerprint of COVID-19,” said co-founder and CEO Jia Zhunan. “Based on more than six years of research at the National University of Singapore, we have developed [a] highly sophisticated proprietary breath sampling technique and analytical method to achieve high accuracy, sensitivity and specificity.”

The NUS spinout said its ongoing pilot study of 180 people, conducted by the city-state’s National Centre for Infectious Diseases, showed an overall sensitivity of 93% and a specificity of 95%. Breathonix said more trials will be required to improve and validate the accuracy of the technology.

By incorporating disposable mouthpieces and one-way valves, the company said its breathalyzer system could potentially be used for mass screening in high-traffic areas, such as airports, hotels, sports venues and transportation hubs. In addition, Breathonix estimated the total cost could reach $20 per test.

“The company is ready to deploy pilots in Singapore in the coming weeks and to extend to international pilots in the coming months, pending regulatory approval,” said co-founder and Chief Operating Officer Du Fang.

Pfizer's vaccine will be available in UK next week

Pfizer's vaccine will be available in UK next week The UK has become the first Western country to approve a Read more

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective

Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective Moderna Inc said it will request authorization for emergency use in Read more

Pfizer's coronavirus vaccine sparks optimism

Pfizer's coronavirus vaccine sparks optimism. The European Commission announced this Wednesday an agreement reached with the pharmaceutical firms Pfizer and Read more

45 vaccine candidates in human trials

45 vaccine candidates in human trials. Governments, companies, health systems and citizens scrutinize with great interest to know when a Read more

Spain will be one of the European economies with a fall in the largest economy

Spain will be one of the European economies with a fall in the largest economy. It was an open secret. Read more

Airbus starts negotiating its industrial plan next week

Airbus starts negotiating its industrial plan next week. Airbus (PA: AIR) recorded 2,686 million euros in losses between January and Read more

We all know that there is enough oil in the world, the problem is in the demand and how it will recover after this crisis

We all know that there is enough oil in the world, the problem is in the demand and how it Read more

Grifols starts the trial to test its immunoglobulin in patients with Covid-19

Grifols starts the trial to test its immunoglobulin in patients with Covid-19. Grifols has announced the start of the clinical Read more

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic

The European Union approves extraordinary funds of 750 billion for recovery after the pandemic.   With a «We did it! Read more

Moderna claims its COVID-19 vaccine produces a "robust" immune response

Moderna claims its COVID-19 vaccine produces a "robust" immune response. Scientists around the world will continue to search for a Read more

Leave a Reply